The antibody 34bE12, available from A Menarini Diagnostics, recognises cytokeratin 1, 5, 10 and 14. It reacts with squamous and adenosquamous cell carcinomas, while adenocarcinoma is negative. In normal tissue, 34bE12 stains stratified epithelia, myoepithelial cells and basal cells in the prostate gland and bronchus. Thus, it is useful as a differential marker for squamous carcinoma and adenocarcinoma as well as for benign and malignant tumours of the prostate gland.
Other News
Latest Issues
Launch Diagnostics provides complete pathology solutions with a comprehensive portfolio of high-quality diagnostic reagents and instrumentation from world leading manufacturers to the Health Services of the United Kingdom. Our associated companies also provide solutions to France, Belgium, and Luxemburg through Launch Diagnostics SAS, to the...
37th European Congress of Pathology
ACV, Vienna, Austria
6 -10 September, 2025
IBMS Congress
The International Convention Centre (ICC), Birmingham
22-25 September, 2025
Diagnostics North East Conference 2025
The Catalyst, Newcastle
3 October
Delivering POCT: Diagnostics in the Community
Manchester Conference Centre
8 October
IHC applications in laboratory practice webinar
Online
11-13 November, 2025